CADL · Insider Trading
Candel Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CADL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Nicoletta Loggia | Director | A | +380 deriv. | — |
| 2026-10-02 | Paul B Manning | Director | A | +2,189 deriv. | — |
| 2026-10-02 | Joseph C Papa | Director | A | +1,325 deriv. | — |
| 2026-09-11 | Paul Peter Tak | Chief Executive Officer | MIXED | −155,245 | −$2.97M |
| 2026-09-10 | Martine Zimmermann | Director | A | +64,000 deriv. | — |
| 2026-08-19 | Seshu Tyagarajan | Chief Technology Officer | Sell | −7,000 | −$84.00K |
| 2026-07-08 | Mark E. Sims | Chief Commercial Officer | A | +285,000 deriv. | — |
| 2026-07-01 | Nicoletta Loggia | Director | A | +381 deriv. | — |
| 2026-07-01 | Francesca Barone | Chief Scientific Officer | Sell | −23,447 | −$235.77K |
| 2026-07-01 | Seshu Tyagarajan | Chief Technology Officer | Sell | −7,000 | −$70.15K |
| 2026-07-01 | Paul B Manning | Director | A | +2,199 deriv. | — |
| 2026-07-01 | Joseph C Papa | Director | A | +1,331 deriv. | — |
| 2026-06-24 | Renee Gaeta | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Gary J. Nabel | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Joseph C Papa | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Christopher Martell | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Paul B Manning | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Nicoletta Loggia | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Maha Radhakrishnan | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Edward J. Benz JR | Director | A | +32,000 deriv. | — |
| 2026-06-24 | Diem Nguyen | Director | A | +32,000 deriv. | — |
| 2026-04-02 | Joseph C Papa | Director | A | +2,795 deriv. | — |
| 2026-04-02 | Nicoletta Loggia | Director | A | +779 deriv. | — |
| 2026-04-02 | Paul B Manning | Director | A | +4,618 deriv. | — |
| 2026-02-26 | Paul B Manning | Director | Buy | +550,458 | +$3.00M |
| 2026-01-28 | Seshu Tyagarajan | Chief Technology Officer | A | +154,000 deriv. | — |
| 2026-01-28 | Charles Schoch | Chief Financial Officer | A | +232,000 deriv. | — |
| 2026-01-28 | Francesca Barone | Chief Scientific Officer | A | +232,000 deriv. | — |
| 2026-01-28 | William Garrett Nichols | Chief Medical Officer | A | +136,500 deriv. | — |
| 2026-01-28 | Paul Peter Tak | Chief Executive Officer | A | +629,000 deriv. | — |
| 2025-07-30 | William Garrett Nichols | Chief Medical Officer | MIXED | — | −$5.33K |
| 2025-07-02 | William Garrett Nichols | Chief Medical Officer | MIXED | — | −$2.93K |
| 2025-06-26 | Charles Schoch | Chief Financial Officer | A | +5,353 | +$25.00K |
| 2025-06-26 | Gary J. Nabel | Director | A | +5,353 | +$25.00K |
| 2025-06-26 | Seshu Tyagarajan | Chief Technology Officer | A | +5,353 | +$25.00K |
| 2025-06-26 | Nicoletta Loggia | Director | A | +2,141 | +$10.00K |
| 2025-06-26 | Francesca Barone | Chief Scientific Officer | A | +4,282 | +$20.00K |
| 2025-06-26 | Paul Peter Tak | Chief Executive Officer | A | +42,826 | +$200.00K |
| 2025-06-26 | Joseph C Papa | Director | A | +64,239 | +$300.00K |
| 2025-06-26 | Christopher Martell | Director | A | +111,349 | +$520.00K |
| 2025-06-26 | Paul B Manning | Director | A | +1,070,663 | +$5.00M |
| 2025-06-24 | Charles Schoch | Chief Financial Officer | A | +50,000 deriv. | — |
| 2025-06-18 | Christopher Martell | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Renee Gaeta | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Nicoletta Loggia | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Paul B Manning | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Joseph C Papa | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Gary J. Nabel | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Diem Nguyen | Director | A | +14,240 deriv. | — |
| 2025-06-18 | Edward J. Benz JR | Director | A | +14,240 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Paul B Manning | Director | 2,984,752 | $24.50M |
| Christopher Martell | Director | 411,564 | $3.38M |
| Laura K. Aguilar | 10%+ Owner | 191,443 | $1.57M |
| Estuardo Aguilar-Cordova | 10%+ Owner | 180,861 | $1.48M |
| Paul Peter Tak | Chief Executive Officer | 172,700 | $1.42M |
| Joseph C Papa | Director | 102,271 | $839.64K |
| Francesca Barone | Chief Scientific Officer | 77,362 | $635.14K |
| Seshu Tyagarajan | Chief Technology Officer | 76,865 | $631.06K |
| William Garrett Nichols | Chief Medical Officer | 52,493 | $430.97K |
| Charles Schoch | Chief Financial Officer | 43,391 | $356.24K |
| Diem Nguyen | Director | 10,000 | $82.10K |
| Gary J. Nabel | Director | 5,353 | $43.95K |
| Nicoletta Loggia | Director | 2,141 | $17.58K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CADL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.